5/5-Cognitive Neuroscience Task Reliability & Clinical Applications Consortium

5/5-认知神经科学任务可靠性

• 批准号: 7812309
• 负责人: ANGUS W MACDONALD
• 金额: $ 27.73万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7812309
• 关键词: Activities of Daily Living; Address; Adverse effects; Aging; Area; Awareness; Basic Science; Behavioral; Behavioral Paradigm; Biocompatible Materials; Bioinformatics; Biological; Biological Markers; Brain; Brain imaging; Characteristics; Clinical; Clinical Investigator; Clinical Trials; Clinical assessments; Cognition; Cognitive; Cognitive deficits; Collaborations; Computer Systems; Consensus; Data; Data Analyses; Data Storage and Retrieval; Development; Ensure; Equipment; Evaluation; Explosion; Floor; Functional Imaging; Functional Magnetic Resonance Imaging; Funding; Genetic Polymorphism; Goals; Healthcare; Hour; Human; Image; Image Analysis; Impaired cognition; Individual; Individual Differences; Intervention; Knowledge; Lead; Length; Letters; Life; Linear Models; Literature; Maintenance; Measurement; Measures; Mediator of activation protein; Mental disorders; Methods; Modeling; Modification; Multi-Institutional Clinical Trial; National Institute of Mental Health; Neurosciences Research; Occupations; Outcome; Parents; Patients; Pattern; Perception; Performance; Persons; Pharmaceutical Preparations; Positioning Attribute; Principal Component Analysis; Process; Property; Psychometrics; Recording of previous events; Recruitment Activity; Research; Research Infrastructure; Retrieval; Sampling; Schizophrenia; Series; Signal Transduction; Site; Standardization; Stimulus; System; Task Performances; Testing; Time; Training; Translating; Translation Process; Translations; Universities; Validation; Visual; Washington; Work; base; clinical application; cognitive function; cognitive neuroscience; college; design; drug development; effective therapy; experience; functional outcomes; imaging modality; improved; independent component analysis; indexing; interest; meetings; member; neuroimaging; process optimization; public health relevance; relating to nervous system; response; skills; success; symposium; theories; therapy design; treatment effect; treatment response; visual control

DESCRIPTION (provided by applicant): This is a competitive revision in response to NOT-OD-09-058, the ARRA call for Competitive Supplement Applications. In the past decade there has been a growing awareness of the disabling effects of impaired cognition in individuals with schizophrenia and the importance of developing new treatments that target cognitive deficits. During this same period, the cognitive neuroscience field has seen an explosion of new knowledge regarding the neural basis of cognition. The application of this new knowledge to drug development in schizophrenia has lagged significantly behind overall progress in cognitive neuroscience, in large part due to the lack of data on the measurement properties of tasks used in cognitive neuroscience. This concern led to the Cognitive Neuroscience Research To Improve Cognition in Schizophrenia (CNTRICS) initiative, which conducted a series of conferences designed to develop consensus on the constructs and paradigms from cognitive neuroscience that are ripe for translation for use in clinical trials contexts. We were recently funded to start this translation process (Cognitive Neuroscience Task Reliability & Clinical Applications (CNTRACs) Consortium.") for behavioral paradigms. We brought together a collaborative team that represents significant expertise from the many fields necessary for the success of this endeavor. We are focusing on four constructs that span both early (gain control and visual integration in perception) and higher-level (goal maintenance, relational encoding and retrieval) components of human cognitive processing. Is this competitive revision we will extend this work in a highly critical and significant direction that the field has identified as a growing need - the development of well validated, and reliable functional neuroimaging paradigms that can serve as biomarkers for predicting and assessing drug and intervention response to treatments designed to enhance cognition. This focus meets one of the key topic areas for Competitive Supplements identified by the NIMH, namely Biomaterials and Biological Measures for the Study of Mental Disorders, which includes "Systematically collecting and analyzing biological measures (e.g., genetic polymorphisms, brain imaging indexes), which could be used, also in combination with clinically derived variables, to identify predictors of outcome, moderators of treatment response and adverse effects, or mediators and patterns of treatment effects." The end goal for these expanded aims will be to provide the field with: 1) easy to use imaging paradigms of these three cognitive functions that: 2) have been optimized for use in a clinical trials context (efficient, reliable, robust); while 3) maintaining their validity as specific measures of the cognitive and neural processes of interest. We believe that it is feasible to complete this added Aim in the time frame of the ARRA announcement, given that we have an established infrastructure. This set of collaborative R01 proposals meet the goals of the ARRA stimulus by providing for funding for 9 new positions, 3 positions that would allow us to retain staff that would otherwise need to be let go, and 1 position that we can increase from part to full time. PUBLIC HEALTH RELEVANCE: This project has high relevance for public health by significantly improving our ability to translate paradigms developed into the basic cognitive neuroscience literature for use in clinical trials aimed at improving cognition in schizophrenia. Cognitive deficits in schizophrenia are a major predictor of functional outcome in this debilitating illness. Thus, we need to improve our methods for detecting and enhancing cognitive function in schizophrenia in order to help individuals with this illness lead more productive and fulfilling lives.

描述（由申请人提供）：这是响应 NOT-OD-09-058（ARRA 竞争性补充申请呼吁）的竞争性修订。在过去的十年中，人们越来越意识到精神分裂症患者认知受损的致残影响以及开发针对认知缺陷的新疗法的重要性。在同一时期，认知神经科学领域出现了有关认知神经基础的新知识的爆炸式增长。这种新知识在精神分裂症药物开发中的应用明显落后于认知神经科学的整体进展，这在很大程度上是由于缺乏认知神经科学中使用的任务的测量特性的数据。这种担忧催生了“改善精神分裂症认知的认知神经科学研究”(CNTRICS) 计划，该计划举办了一系列会议，旨在就认知神经科学的结构和范式达成共识，这些结构和范式已经成熟，可以转化为用于临床试验环境。我们最近获得资助来启动这个行为范式的翻译过程（认知神经科学任务可靠性和临床应用（CNTRAC）联盟。”）。我们聚集了一个协作团队，代表了这一努力成功所必需的许多领域的重要专业知识。我们专注于跨越早期（获得控制和感知中的视觉整合）和更高层次（目标维护、关系编码和 检索）人类认知处理的组成部分。在这次竞争性修订中，我们将把这项工作扩展到一个非常关键和重要的方向，该领域已经确定了这一日益增长的需求——开发经过充分验证的、可靠的功能性神经影像范式，可以作为生物标志物，用于预测和评估药物和干预对旨在增强认知的治疗的反应。这一重点符合 NIMH 确定的竞争性补充剂的关键主题领域之一， 即用于精神障碍研究的生物材料和生物测量，其中包括“系统地收集和分析生物测量（例如，遗传多态性、脑成像指数），也可与临床衍生变量结合使用，以确定结果的预测因素、治疗反应和不良反应的调节因素，或治疗效果的调节因素和模式。”这些扩展目标的最终目标 将为该领域提供：1）这三种认知功能的易于使用的成像范例：2）已针对临床试验环境中的使用进行了优化（高效、可靠、稳健）； 3）保持其作为感兴趣的认知和神经过程的具体测量的有效性。我们相信，鉴于我们已经建立了基础设施，在 ARRA 公告的时间范围内完成这一新增目标是可行的。这个 一系列协作 R01 提案通过为 9 个新职位提供资金来满足 ARRA 刺激计划的目标，其中 3 个职位将使我们能够留住本来需要裁掉的员工，以及 1 个职位我们可以从兼职增加到全职。 公共健康相关性：该项目通过显着提高我们将开发的范式转化为基础认知神经科学文献以用于旨在改善精神分裂症认知的临床试验的能力，与公共健康具有高度相关性。精神分裂症的认知缺陷是这种使人衰弱的疾病功能结果的主要预测因素。因此，我们需要改进检测和增强精神分裂症认知功能的方法，以帮助患有这种疾病的人过上更富有成效和更充实的生活。